Celecoxib Reduces Proliferation Biomarker in Lung Cance Prevention Trial
Short-term treatment with high-dose celecoxib reduced expression levels for a biomarker associated with precancerous lung lesions in a chemoprevention study of about 200 current and former smokers, according to data presented June 2 at the annual meeting of the American Society of Clinical Oncology.The randomized, double-blind prospective study found a significant reduction in Ki-67 expression, as well as reduced levels of cyclooxygenase-2 (COX-2) in patients who received 400 mg twice daily of celecoxib (Celebrex) for 3 months.
“We cannot sit here and say that taking celecoxib is going to prevent lung cancer. That needs further, larger-scale studies,” Dr. Edward S. Kim, the lead author and a medical oncologist at the University of Texas M.D. Anderson Cancer Center, Houston, cautioned at a June 1 press briefing at the ASCO annual meeting.
This entry was posted on Friday, June 6th, 2008 at 11:14 am and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.